BG101139A - Heteroatoms-containing cyclopentanopyridyloxazolidinons - Google Patents

Heteroatoms-containing cyclopentanopyridyloxazolidinons

Info

Publication number
BG101139A
BG101139A BG101139A BG10113997A BG101139A BG 101139 A BG101139 A BG 101139A BG 101139 A BG101139 A BG 101139A BG 10113997 A BG10113997 A BG 10113997A BG 101139 A BG101139 A BG 101139A
Authority
BG
Bulgaria
Prior art keywords
heteroatoms
cyclopentanopyridyloxazolidinons
particularas
containingcyclopentanopyridyloxazolidinons
antibacerial
Prior art date
Application number
BG101139A
Other languages
Bulgarian (bg)
English (en)
Inventor
Andreas Stolle
Dieter Haebich
Bernd Riedl
Martin Ruppelt
Stephan Bartel
Walter Guarnieri
Hanno Wild
Rainer Endermann
Hein-Peter Kroll
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of BG101139A publication Critical patent/BG101139A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG101139A 1996-01-18 1997-01-16 Heteroatoms-containing cyclopentanopyridyloxazolidinons BG101139A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19601627A DE19601627A1 (de) 1996-01-18 1996-01-18 Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone

Publications (1)

Publication Number Publication Date
BG101139A true BG101139A (en) 1998-04-30

Family

ID=7783042

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101139A BG101139A (en) 1996-01-18 1997-01-16 Heteroatoms-containing cyclopentanopyridyloxazolidinons

Country Status (21)

Country Link
US (1) US5869659A (fr)
EP (1) EP0785201A1 (fr)
JP (1) JPH09202787A (fr)
KR (1) KR970059170A (fr)
AU (1) AU1012397A (fr)
BG (1) BG101139A (fr)
BR (1) BR9700716A (fr)
CA (1) CA2195177A1 (fr)
CZ (1) CZ15897A3 (fr)
DE (1) DE19601627A1 (fr)
EE (1) EE9700020A (fr)
HU (1) HU9700152D0 (fr)
IL (1) IL120016A0 (fr)
MA (1) MA24062A1 (fr)
NO (1) NO970210L (fr)
PL (1) PL317985A1 (fr)
SG (1) SG50001A1 (fr)
SK (1) SK6997A3 (fr)
TN (1) TNSN97010A1 (fr)
TR (1) TR199700039A2 (fr)
ZA (1) ZA97393B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562844B2 (en) 1998-01-23 2003-05-13 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
WO1999037630A1 (fr) 1998-01-23 1999-07-29 Versicor, Inc. Banques combinatoires d'oxazolidinones, compositions a base de tels composes et procedes de preparation
US7002020B1 (en) 1998-01-23 2006-02-21 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
KR20010052615A (ko) 1998-06-05 2001-06-25 다비드 에 질레스 옥사졸리디논 유도체, 이것의 제조 방법 및 이것을함유하는 약학 조성물
US6441005B1 (en) 1999-07-28 2002-08-27 Pharmacia & Upjohn Company Oxazolidinone compounds and compositions, and methods of using the same
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
MY127336A (en) 2000-03-22 2006-11-30 Upjohn Co Container for linezolid iv solution
US6514529B2 (en) 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
JP2004501965A (ja) 2000-06-30 2004-01-22 ファルマシア・アンド・アップジョン・カンパニー 細菌感染を治療するための組成物および方法
US6423844B1 (en) 2001-06-06 2002-07-23 The United States Of America As Represented By The Secretary Of The Navy Process for making 1,2,4-triazolo[4,3-a][1,3,5]triazine-3,5,7-triamine
US7141588B2 (en) * 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
WO2004014897A1 (fr) * 2002-08-12 2004-02-19 Pharmacia & Upjohn Company Llc N-aryl-2-oxazolidinones et leurs derives
WO2004045616A1 (fr) * 2002-11-21 2004-06-03 Pharmacia & Upjohn Company Llc Derives de n-(4-(piperazine-1-yl)-phenyl-2-oxazolidinone-5-carboxamides et composes associes servant d'agents antibacteriens
EP1594494A1 (fr) * 2003-02-07 2005-11-16 Warner-Lambert Company LLC Derives d'oxazolidinone n-substitues par un noyau bicyclique, utilises comme agents antibacteriens
EP1594865A2 (fr) * 2003-02-07 2005-11-16 Warner-Lambert Company LLC Agents antibacteriens
US7012088B2 (en) * 2003-02-24 2006-03-14 Pharmacia & Upjohn Company Indolone oxazolidinones and derivatives thereof
US20040204463A1 (en) * 2003-04-01 2004-10-14 Harris Christina Renee N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
US7304050B2 (en) * 2003-09-16 2007-12-04 Pfizer Inc. Antibacterial agents
WO2005082900A2 (fr) * 2004-01-28 2005-09-09 Pharmacia & Upjohn Company Llc Amidoxines d'oxazolidinone utilisees en tant qu'agents antibacteriens
BRPI0513083A (pt) * 2004-08-06 2008-04-22 Pharmacia & Upjohn Co Llc oxazolidinonas contendo oxindóis como agentes antibacterianos
US7981893B2 (en) * 2006-10-19 2011-07-19 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
NZ618135A (en) 2009-10-26 2015-05-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
KR101978537B1 (ko) 2011-10-19 2019-05-14 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
US9403829B2 (en) 2011-12-02 2016-08-02 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use
JP6114317B2 (ja) 2012-02-24 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
MX2015009209A (es) 2013-01-16 2016-03-17 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
EA030726B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
CA2908957C (fr) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Polytherapie comportant un compose dihydropyrazino-pyrazine et un antagoniste d'un recepteur des androgenes pour le traitement du cancer de la prostate
CA2908353C (fr) 2013-04-17 2021-11-02 Signal Pharmaceuticals, Llc Traitement du cancer par des dihydropyrazino-pyrazines
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
AU2014254059B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer
HK1223286A1 (zh) 2013-05-29 2017-07-28 西格诺药品有限公司 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131552B1 (fr) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Méthodes de traitement du cancer à l'aide d'une polythérapie avec des inhibiteurs de la kinase tor
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
ES2959860T3 (es) 2017-06-22 2024-02-28 Celgene Corp Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705799A (en) * 1983-06-07 1987-11-10 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents
US4921869A (en) * 1987-10-09 1990-05-01 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4985429A (en) * 1987-10-09 1991-01-15 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4801600A (en) * 1987-10-09 1989-01-31 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4965268A (en) * 1987-10-09 1990-10-23 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4942183A (en) * 1987-10-16 1990-07-17 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
ATE112773T1 (de) 1988-09-15 1994-10-15 Upjohn Co 5-indolinyl-5-beta-amidomethyloxazolidin-2-one, 3-(substituierte kondensierte)phenyl-5-beta amidomethyloxazolidin-2-one und 3-(nitrogen- substituierte)phenyl-5-beta-amidomethyloxazolid n-2-one.
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
JP2679745B2 (ja) * 1989-06-29 1997-11-19 明治製菓株式会社 アゾール誘導体及びそれらを有効成分とする抗潰瘍剤
JP2669579B2 (ja) * 1991-10-23 1997-10-29 エーザイ株式会社 オキサゾリドン誘導体
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
TW286317B (fr) 1993-12-13 1996-09-21 Hoffmann La Roche
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone

Also Published As

Publication number Publication date
BR9700716A (pt) 1998-10-06
AU1012397A (en) 1997-07-24
HU9700152D0 (en) 1997-03-28
EE9700020A (et) 1997-08-15
IL120016A0 (en) 1997-04-15
TNSN97010A1 (fr) 2005-03-15
TR199700039A2 (tr) 1997-08-21
MA24062A1 (fr) 1997-10-01
NO970210D0 (no) 1997-01-17
EP0785201A1 (fr) 1997-07-23
ZA97393B (en) 1997-07-17
JPH09202787A (ja) 1997-08-05
CZ15897A3 (en) 1997-08-13
KR970059170A (ko) 1997-08-12
CA2195177A1 (fr) 1997-07-19
SG50001A1 (en) 1998-06-15
NO970210L (no) 1997-07-21
MX9700388A (es) 1997-07-31
SK6997A3 (en) 1997-09-10
DE19601627A1 (de) 1997-07-24
PL317985A1 (en) 1997-07-21
US5869659A (en) 1999-02-09

Similar Documents

Publication Publication Date Title
BG101131A (en) 2-oxo-and 2-thio-1,2-dihydroquinolinyl-oxazolidinons
EP0764082A4 (fr) Composition odorante, son procede et systeme de liberation
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
ZA977695B (en) 1,4-heterocyclic metalloprotease inhibitors.
EP0667586A3 (fr) Système de production de banques de données.
ZA977693B (en) 1,3-diheterocyclic metalloprotease inhibitors.
EP0650844A3 (fr) Imprimantes de type navette et méthodes pour sa mise en oeuvre.
EP0714738A4 (fr) Disque d'appui pour ciseaux, et ciseaux le mettant en oeuvre
ZA949151B (en) 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents.
GB9706597D0 (en) Compositions,processes and uses
GB9608488D0 (en) Compositions, processes and uses
BG102395A (en) New phenylamidine derivatives, method for their preparation and application as medicamentous forms
ZA97944B (en) N: 1 Transcoder.
ZA9711555B (en) Face masks.
ZA97188B (en) Disinfecting compositions and processes for disinfecting surfaces.
UA48245C2 (uk) ЗАМІЩЕНІ 1,2,3,4-ТЕТРАГІДРО-2-ДИБЕНЗОФУРАНАМІНИ ТА 2-АМІНОЦИКЛОГЕПТА[B]БЕНЗОФУРАНИ, ФАРМАЦЕВТИЧНА ЛІКАРСЬКА ФОРМА ТА СПОСІБ ПІДВИЩЕННЯ АКТИВАЦІЇ 5-НТ<sub>1F</sub> РЕЦЕПТОРА У ССАВЦЯ
ZA949874B (en) B3-adrenergic agents, benzodioxole dicarboxylates and their use in pharmaceutical compositions.
GB9420616D0 (en) Method, compositions and use
GB9608489D0 (en) Compositions, processes and uses
ZA97224B (en) Process for recovering minerals and compositions for use in this.
GB2289775B (en) I.S Machine
GB9608491D0 (en) Compositions, processes and uses
GB9706136D0 (en) Compositions,processes and uses
HU9600727D0 (en) Triaryl-ethylene derivatives for use in therapy
GB9705848D0 (en) Compositions, processes and uses